CCL

Összesen 1 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM041459
Első szerző:Buzzetti, Raffaella
Cím:C-peptide response and HLA genotypes in subjects with recent-onset type 1 diabetes after immunotherapy with DiaPep277 : an exploratory study / Raffaella Buzzetti, Simona Cernea, Antonio Petrone, Marco Capizzi, Marialuisa Spoletini, Simona Zampetti, Chiara Guglielmi, Chiara Venditti, Paolo Pozzilli, DiaPep Trialists Group
Dátum:2011
ISSN:0012-1797
Megjegyzések:OBJECTIVETo investigate whether lower risk HLA class II genotypes would influence the efficacy of DiaPep277 therapy in protecting ?-cell function evaluated by C-peptide secretion in recent-onset type 1 diabetic subjects.RESEARCH DESIGN AND METHODSData were collected from type 1 diabetic subjects enrolled in multicenter phase II studies with a randomized, double-blind, and placebo-controlled design in whom fasting and stimulated C-peptide levels were measured. HLA genotypes were classified in high, moderate, and low risk categories.RESULTSA total of 146 subjects (aged 4.3 to 58.5 years) were enrolled, including 76 children (<18 years old) and 70 adults. At baseline, there was a significant increase in fasting, maximal, and area under the curve (AUC) C-peptide from high to moderate and low risk HLA genotypes in adults (P for trend <0.04) but not in children. Children showed a decrease of the three parameters over time regardless of therapy and HLA genotype. DiaPep277-treated adults with low risk genotype had significantly higher maximal and AUC C-peptide versus placebo at 12 months (0.04 ? 0.07 vs. ?0.28 ? 0.09 nmol/L, P < 0.01, and 0.53 ? 1.3 vs. ?4.59 ? 1.5 nmol/L, P < 0.05, respectively). In the moderate risk genotype group, ?maximal and AUC C-peptide values were significantly higher in DiaPep277-treated versus placebo-treated patients (P < 0.01 and P < 0.05, respectively).CONCLUSIONSThis exploratory study demonstrates that type 1 diabetic adults with low and moderate risk HLA genotypes benefit the most from intervention with DiaPep277; the only subgroup with an increase of C-peptide at 12 months after diagnosis was the low risk DiaPep277-treated subgroup.
Tárgyszavak:Orvostudományok Klinikai orvostudományok módszertani levél
open access article
feltáró tanulmány
külföldön készült közlemény
Megjelenés:Diabetes. - 60 : 11 (2011), p. 3067-3072. -
További szerzők:Cernea, Simona Petrone, Antonio Capizzi, Marco Spoletini, Marialuisa Zampetti, Simona Guglielmi, Chiara Venditti, Chiara Pozzilli, Paolo Barkai László (1958-) (gyermekgyógyász) DiaPep Trialists Group
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1